Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dociparstat in AML
NCT02056782Phase 1Completed
- Sponsor
- Chimerix Inc.
- Start
- Dec 2013
- Primary completion
- Feb 2015
- Modality
- Small Molecules
01
Overview
Phase 1, open-label, single-arm trial of dociparstat sodium in acute myeloid leukemia (AML), sponsored by Chimerix Inc. Primary endpoints: Time to Transfusion-independent Platelet Recovery and Safety and Tolerability of Dociparstat. Started Dec 2013; status: completed.
02
Drugs
dociparstat sodium
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02056782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02056782.